Capricor Sues Partner NS Pharma Over Deramiocel Commercialization Pricing Flaws
Just weeks ahead of its critical FDA review, Capricor Therapeutics has launched a high-stakes legal battle against its U.S. commercialization and distribution partner, Nippon Shinyaku (and its U.S. subsidiary, NS Pharma). The lawsuit, filed in July 2026, seeks to rescind their U.S. distribution agreement over what Capricor describes as critical "pricing flaws" that would block insured patient access to its investigational Duchenne muscular dystrophy (DMD) cardiomyopathy cell therapy, deramiocel (CAP-1002).
The Core of the Dispute
Capricor alleges that NS Pharma failed to adequately prepare for the commercial rollout of deramiocel and refused to correct fundamental pricing structures in their commercialization agreement. According to industry reports:
"It's also suing its own commercial partner, Nippon Shinyaku/NS Pharma, to rescind their U.S. distribution deal over a pricing flaw it says would block insured patient access..."
This legal escalation has significant commercial implications. In response to the litigation, financial analysts have updated their launch models for the drug. Cantor Fitzgerald removed an expected $80 million milestone payment previously modeled for Q4 2026 and postponed its projected U.S. commercial launch timeline for deramiocel from late 2026 to 2027.
Regulatory Context
The commercial standoff unfolds at a highly delicate time for the clinical asset. Capricor's BLA for deramiocel is currently under active FDA review following a previous Complete Response Letter (CRL) issued last year. The upcoming regulatory milestones remain on track despite the partner dispute:
- July 29, 2026: The FDA Cellular, Tissue, and Gene Therapies Advisory Committee is scheduled to convene to discuss and vote on deramiocel.
- August 22, 2026: The FDA's PDUFA target action date for the drug.
If approved, deramiocel would be the first therapy to address both the skeletal and cardiac manifestations of Duchenne muscular dystrophy, which is typically fatal due to progressive heart failure. Capricor's decision to seek rescission suggests the company is prepared to take over U.S. distribution itself or seek a new commercial partner if the FDA grants approval in August.